Skip to main content Skip to section navigation Skip to footer

Mydecine Innovations Group Inc.

  • Home
  • About
    • Overview
    • Company History
    • Acquisitions
    • Partnerships
    • Leadership Team
    • Board of Directors
    • Research & Development Team
    • Medical, Scientific and Technology Advisory Board
  • Our Approach
    • IP & Drug Development
    • Clinical Trials
    • Technology
  • Drug Supply
    • Investigational Drug Supply
    • Special Access Program
  • News & Media
    • Blog
    • Press Releases
    • In The News
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Results
    • Stock Data
    • SEDAR
    • Governance
    • FAQs
  • Contact
  • Careers
  • Search

In The News

News & Media

News & Media

  • Blog
  • Press Releases
  • In The News
May 3, 2022

Why Psychedelic Drugs May Become a Key Treatment for PTSD and Depression

Apr 8, 2022

Funders at Johns Hopkins Shape The Future of Psychedelic Research

Apr 1, 2022

Canada’s SAP Expansion Signals a Step Forward for Psychedelics

Feb 25, 2022

New compound could make microdosing “heart-safe”

Feb 1, 2022

Mydecine submits pre-IND briefing package to FDA for MYCO-001 smoking cessation clinical trial

Feb 1, 2022

Psychedelic Stocks Remain Solid Long-Term Investment: Mydecine CEO On Industry Outlook

Jan 28, 2022

Psychedelic Business Spotlight — January 28

Jan 13, 2022

Mydecine Is Poised To Provide A Psychedelic Specialized Program Throughout Canada

Jan 6, 2022

The Future of Psilocybin Therapy with Josh Bartch, CEO of Mydecine Innovation Group on Gamechangers®

Dec 30, 2021

Mydecine’s Dr. Rick Barnett On Psychedelics In The Fight Against Addiction

rss_feed RSS
  • 1
  • 2
  • 3
  • 4
  • 5
  • arrow_forward

Sign up for our Newsletter!

twitter Linkedin Instagram
©2022 Mydecine Innovations Group Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap